Website
News25/Ratings12
News · 26 weeks54-45%
2025-10-262026-04-19
Mix2890d
- Insider10(36%)
- Other9(32%)
- SEC Filings6(21%)
- Earnings2(7%)
- Analyst1(4%)
Latest news
25 items- PRGoodRx Announces Date for First Quarter 2026 Earnings Release and Conference CallGoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor
- INSIDERSEC Form 4 filed by Mcginnis Christopher A4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERSEC Form 4 filed by Barnes Wendy Lynn4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- PRGoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay PriceExpands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss Brief Summary: Wegovy® HD is now available on GoodRx at a self-pay price of $399 per month Pricing scales to $798 for two-month supply and $1,197 for three-month supply Available at pharmacies nationwide through GoodRx Consumers can determine eligibility and obtain a prescription through GoodRx for Weight Loss GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month.
- PRGoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies NationwideEligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx Brief Summary: GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx GoodRx is also offering self-pay pricing for Zepbound® (tirzepatide) KwikPen® starting at $299 per month Foundayo and Zepbound KwikPen are available through GoodRx's nationwide pharmacy network GoodRx is helping pharmaceutical manufacturers deliver consumer-direct pricing at scale from day one GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today a
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- INSIDERDirector Rey-Giraud Agnes exercised 192,185 shares at a strike of $0.47, gifted 75,219 shares and received a gift of 75,219 shares, increasing direct ownership by 313% to 352,852 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- PRGoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand MedicationsCollaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc® GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cash prices of up to 85% off at more than 70,000 pharmacies nationwide. The collaboration i
- INSIDERChief Accounting Officer Nabiey Romin converted options into 12,434 shares and covered exercise/tax liability with 5,121 shares, increasing direct ownership by 4% to 183,061 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- PRGoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs Brief Summary: GoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an FDA-approved dual GIP and GLP-1 obesity treatment Through GoodRx Employer Direct, self-insured employers can subsidize Lilly's $449 discounted medication price for Zepbound KwikPen Employer contributions are applied to the medication cost, reducing employee out-of-pocket costs GoodRx integrates manufacturer discounted pricing and employer funding in real time; optional telemedicine supports p
- INSIDERSEC Form 4 filed by Officer Mcginnis Christopher A4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERSEC Form 4 filed by Chief Accounting Officer Nabiey Romin4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERSEC Form 4 filed by Officer Barnes Wendy Lynn4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- ANALYSTGoodRx downgraded by AnalystAnalyst downgraded GoodRx from Overweight to Neutral
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- PRGoodRx Expands Into Employer Market With Launch of "GoodRx Employer Direct"New program combines employer-subsidized discounted cash prices and custom telemedicine solutions with existing health benefits to close coverage gaps and support access to high-impact medications GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx's condition-specific telemedicine solutions, integrating clinical care, prescribing, and pharmacy fulfillm
- INSIDEROfficer Mcginnis Christopher A covered exercise/tax liability with 52,799 shares and converted options into 179,120 shares (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERChief Accounting Officer Nabiey Romin converted options into 4,804 shares and covered exercise/tax liability with 1,979 shares, increasing direct ownership by 2% to 175,748 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERChief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 5,215 shares, increasing direct ownership by 5% to 172,923 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- PRGoodRx Powers Pricing for Leading Brand Medications on TrumpRxBrief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer's essential brand medications spanning women's health, arthritis, and more By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on T